This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEC0I1CI_M.jpgInvestingPro subscribers got this news before anyone else. Start your 7-day trial to get on board.
Norfolk Southern (NYSE:NSC) shares rose more than 2% pre-market today after two Wall Street firms upgraded the company, as InvestingPro reported in real time.
Wells Fargo upgraded the company to Overweight from Equal Weight and raised its price target to $250.00 from $225.00. Meanwhile, Citi upgraded to Buy from Neutral and raised its price target to $257.00 from $226.00.
Last month, the company reported its Q1 earnings, highlighted by an EPS beat and in-line revenues.
UBS upgraded DraftKings (NASDAQ:DKNG) to Buy from Neutral and raised its price target to $30.00 from $19.00. Shares gained more than 3% pre-market today.
Earlier this month, the company reported its Q1 results, with both EPS and revenues coming in better than the Street estimates.
Citi upgraded Union Pacific (NYSE:UNP) to Buy from Neutral and raised its price target to $237.00 from $229.00. Shares rose more than 1% pre-market today.
JPMorgan upgraded AnaptysBio (NASDAQ:ANAB) to Neutral from Underweight while slightly lowering its price target to $30.00 from $31.00, noting it doesn’t see significant downside risk from current levels, given near and intermediate-term focus is on clinical execution for lead programs rather than catalysts – ANB032 and rosnilimab.
On the other hand, the firm doesn’t see upside potential from the core pipeline, while noting that it’s important to monitor competition for each of the aforementioned mechanisms/products. This balance forms the basis of its Neutral rating, and the firm expects AnaptysBio shares to perform in line with biotech peers.
In fast-moving markets, every second counts – and InvestingPro subscribers are always one step ahead with lightning-quick updates.
Start your free 7-day trial now.
